Weekly injection under investigation for metabolic steatohepatitis (MASH) and obesity. Not approved in any country.
Regulatory status
In clinical trials
Family
Dual GLP-1 and glucagon receptor agonist
Scientific evidence
Moderate
Number of findings
1
Where it acts
Digestive and weight · Hormones and metabolism
Also known as
pemvidutide, ALT-801
Regulatory status
FDA (US): Not approved (phase 3 in MASH planned for 2026).
EMA (EU): Not approved.
Dose
There is no established dose in humans. In the phase 2b IMPACT trial, 1.2 or 1.8 mg subcutaneously once a week for 24 weeks was used.
Safety
Digestive effects typical of the class. In IMPACT, dropouts due to adverse effects were low (0–1.2% vs 2.4% with placebo) and there were no serious effects attributed to the drug. Use only in clinical trials or research, under medical supervision; buying it is not recommended.
Effect by goal · level of evidence
Resolution of steatohepatitis (MASH)
improvesModerateRCT (AA)in people
59% vs 19%
IMPACT phase 2b trial (212 adults with MASH and F2–F3 fibrosis, 24 weeks): MASH resolved in 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% with placebo. The improvement in fibrosis was not significant (32–35% vs 26%). Weight loss of 5–6% vs 1%.
Activates GLP-1 (reduced appetite) and glucagon receptors in a balanced ratio. The glucagon component acts directly on the liver, increasing fat burning and reducing liver fat and inflammation.
What the evidence says
In people
Resolution of steatohepatitis (MASH). Phase 2b IMPACT trial (212 adults with MASH and F2–F3 fibrosis, 24 weeks): MASH resolved in 59.1% (1.2 mg) and 52.1% (1.8 mg) vs 19.1% with placebo. The improvement in fibrosis was not significant (32–35% vs 26%). Weight loss of 5–6% vs 1%. PubMed 41237796